Accurkardia headquarters details
101 Ave of the Americas suite 843
New York City
New York
10013
United States
2019
Location map
Open in Google MapsAll Accurkardia office locations
| City | State / region | Country | Type |
|---|---|---|---|
| New York City HQ | New York | United States | Headquarters |
About Accurkardia
Accurkardia (Private) is headquartered in New York City, New York, United States. Founded in 2019, the company operates across 1 countries with approximately 8 employees worldwide.
Where is Accurkardia's main office?
Accurkardia's main headquarters office is located at 101 Ave of the Americas suite 843, New York City, New York 10013. This serves as the company's primary corporate address and is home to its executive leadership team.
Accurkardia regional offices
Beyond its headquarters in New York City, Accurkardia maintains 2 offices across 1 countries. Regional offices span 1 countries.
Accurkardia contact information
The main switchboard for Accurkardia headquarters can be reached at 7187083522. For investor relations, visit accurkardia.com/investor-relations.
What does Accurkardia do?
AccurKardia is an ECG-led diagnostics software company transforming ECG data into a more powerful diagnostic tool and broad biomarker to improve patient outcomes and save lives globally. Its cloud-based platform includes AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) that delivers fully automated, near real-time ECG interpretation and integrates seamlessly into existing clinical workflows. AccurECG™ was named “Best New ECG Technology” at the 2025 MedTech Breakthrough Awards. AccurKardia’s pipeline includes AK+ Guard™—an AI-driven hyperkalemia detection solution using Lead I ECG data to help identify life-threatening high potassium levels earlier in patients with CKD and ESRD—which received FDA Breakthrough Device Designation and acceptance into FDA’s Total Product Life Cycle (TAP) program in December 2024; and AK-AVS™, an AI model for aortic stenosis detection via 12-lead ECGs, which received FDA Breakthrough Device Designation in October 2024. AccurKardia completed the 2024 MedTech Innovator (MTI) cohort and was one of five companies selected for the American Heart Association’s inaugural Heart & Brain Health Accelerator track within MTI. AccurKardia also completed Cohort 3 of Mayo Clinic Platform_Accelerate in 2023. (AK+ Guard™ and AK-AVS™ are investigational and not commercially available.)
Frequently asked questions
Where is Accurkardia headquarters?
Accurkardia's headquarters is located at 101 Ave of the Americas suite 843, New York City, New York 10013, United States.
How many offices does Accurkardia have?
Accurkardia operates 2 offices across 1 countries as of 2026.
What is Accurkardia's corporate address?
The official corporate address is 101 Ave of the Americas suite 843, New York City, New York 10013.
When was Accurkardia founded?
Accurkardia was founded in 2019 and has grown to employ approximately 8 people worldwide.
What is Accurkardia's phone number?
The main phone number for Accurkardia headquarters is 7187083522.